Hamad, S. H., Montgomery, S. A., Simon, J. M., Bowman, B. M., Spainhower, K. B., Murphy, R. M., … Weissman, B. E. (2022). Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene, 41(39), 4485. https://doi.org/10.1038/s41388-022-02442-3

Hamad, Samera H., Stephanie A. Montgomery, Jeremy M. Simon, Brittany M. Bowman, Kyle B. Spainhower, Ryan M. Murphy, Erik S. Knudsen, et al. “Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.” Oncogene 41, no. 39 (September 2022): 4485. https://doi.org/10.1038/s41388-022-02442-3.

Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, et al. Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. 2022 Sep;41(39):4485.

Hamad, Samera H., et al. “Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.” Oncogene, vol. 41, no. 39, Sept. 2022, p. 4485. Pubmed, doi:10.1038/s41388-022-02442-3.

Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. 2022 Sep;41(39):4485.